Your cart is currently empty!.
You may check out all the available products and buy some in the shop.
Continue Shopping
In Stock
GLP-1 Analogs
RTT 30mg (Rodeo Drive)
✓ 99.8% Purity (HPLC)
Molecular Weight
4728.47 g/mol
CAS Number
2381089-83-2
Form
Lyophilized powder
Use
Research only
$300.00
We accept
- Ships within 1–2 business days, discreetly packaged
- Lyophilized for research flexibility
- Third-party HPLC & endotoxin tested per batch
About
What is RTT 30mg (Rodeo Drive)?
Retatrutide (compound code LY3437943) is an investigational 39-amino-acid peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is the first compound of its class to advance into Phase 3 clinical research for obesity and type 2 diabetes.
Mechanism of Action
Simultaneously activates three incretin-related receptors: GLP-1 (glucose-dependent insulin release + satiety), GIP (insulin secretion + adipose function), and glucagon (hepatic energy expenditure). Published studies describe additive effects on energy expenditure versus GLP-1 monotherapy.
Discovery & Context
Developed by Eli Lilly. Phase 2 results published in NEJM (2023) reported 24.2% mean body-weight reduction at 48 weeks with the 12 mg dose. Continues in comparative metabolic research.
Research use only. Language such as "may," "appears to," and "has been shown in published studies" is used throughout to reflect the pre-clinical nature of this literature. Not intended for human consumption, diagnosis, or treatment.
Background
Research Context
Published research literature covers the following areas:
- GLP-1 / GIP / glucagon receptor pharmacology
- Incretin research
- Comparative studies vs. semaglutide / tirzepatide
- Metabolic homeostasis
- Body composition research
LAR supplies this compound as a reference standard to qualified laboratories. No dosing schedules, administration methods, or human-use guidance is provided or implied.
Literature
Selected References
- Jastreboff AM. et al. (2023). Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526. NEJM.org ↗
- Coskun T. et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 34(9), 1234–1247. PubMed 36070683 ↗
Handling
Storage & Stability
Sealed vial: Stable at refrigerated temperatures (2–8 °C) for up to 24 months. Stable at room temperature (up to 25 °C) for 30 days during shipping.
After opening: Refrigerate at 2–8 °C and use within 30 days. Protect from light. Do not freeze after opening.
Visual check: Solution should remain clear. Discard if discoloration or precipitate appears.
Lab Work
Certificate of Analysis
Every batch is independently tested for purity, mass, and endotoxin load. Click any report to view the full analysis.
Questions
Frequently Asked
Is this FDA approved?
No. Research peptides supplied by LAR are reference materials for laboratory investigation. They are not approved by the FDA or any national regulatory body for human use.
Does this vial require reconstitution?
Yes. Vials ship as lyophilized powder, giving your lab control over solvent selection and final concentration. Reconstitution should follow your laboratory's standard practice.
How is purity verified?
Each manufacturing batch is tested by an independent third-party laboratory using HPLC-UV analysis. The full report, including chromatogram and mass spectrometry, is available above.
How long does shipping take?
Orders ship within 1–2 business days via discreet packaging.
